Advances in pharmacotherapy for bronchiectasis in adults

• Published in: Expert opinion on pharmacotherapy Vol. 24; no. 9; p. 1075
• Main Authors: Zhang, Xiao-Xian, Chen, Zhao-Ming, He, Zhen-Feng, Guan, Wei-Jie
• Format: Journal Article
• Language: English
• Published: England 13.06.2023
• Subjects: Administration, Inhalation; Anti-Bacterial Agents - therapeutic use; Anti-Inflammatory Agents - therapeutic use; Bronchiectasis - drug therapy; Bronchiectasis - microbiology; Humans; Bronchiectasis; inhaled antibiotics; pharmacotherapy; exacerbation; neutrophil inflammation
• ISSN: 1744-7666
• DOI: 10.1080/14656566.2023.2210763

Bronchiectasis has become a growing concern of chronic airway disease because of the enormous socioeconomic burden. Four cardinal interdependent components - impaired airway defense, recurrent airway infections, inflammatory response, and airway damage, in conjunction with the underlying etiology, have collectively played a role in modulating the vicious vortex of the pathogenesis and progression of bronchiectasis. Current pharmacotherapy aims to target at these aspects to break the vicious vortex. The authors retrieve and review, in MEDLINE, Web of Science and ClinicalTrials.gov registry, the studies about pharmacotherapy for bronchiectasis from these aspects: antibiotics, mucoactive medications, bronchodilators, anti-inflammatory drug, and etiological treatment. Future drug development and clinical trials of bronchiectasis need to pay more attention to the different phenotypes or endotypes of bronchiectasis. There is a need for the development of novel inhaled antibiotics that could reduce bacterial loads, improve quality-of-life, and decrease exacerbation risks. More efforts are needed to explore the next-generation neutrophil-targeted therapeutic drugs that are expected to ameliorate respiratory symptom burden, reduce exacerbation risks, and hinder airway destruction in bronchiectasis.